<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To present a critical discussion of the efficacy of the faecal <z:chebi fb="1" ids="15361">pyruvate</z:chebi> kinase isoenzyme type M2 (faecal M2-PK) test for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) screening based on the currently available studies </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A literature search in PubMed and Embase was conducted using the following search terms: fecal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> M2-PK, faecal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> M2-PK, fecal M2-PK, faecal M2-PK, fecal <z:chebi fb="1" ids="15361">pyruvate</z:chebi> kinase, faecal <z:chebi fb="1" ids="15361">pyruvate</z:chebi> kinase, <z:chebi fb="1" ids="15361">pyruvate</z:chebi> kinase stool and M2-PK stool </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Stool samples from 704 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and from 11 412 healthy subjects have been investigated for faecal M2-PK concentrations in seventeen independent studies </plain></SENT>
<SENT sid="3" pm="."><plain>The mean faecal M2-PK sensitivity was 80.3%; the specificity was 95.2% </plain></SENT>
<SENT sid="4" pm="."><plain>Four studies compared faecal M2-PK head-to-head with guaiac-based faecal occult blood test (gFOBT) </plain></SENT>
<SENT sid="5" pm="."><plain>Faecal M2-PK demonstrated a sensitivity of 81.1%, whereas the gFOBT detected only 36.9% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Eight independent studies investigated the sensitivity of faecal M2-PK for <z:mpath ids='MPATH_270'>adenoma</z:mpath> (n = 554), with the following sensitivities: <z:mpath ids='MPATH_270'>adenoma</z:mpath> &lt; 1 cm in diameter: 25%; <z:mpath ids='MPATH_270'>adenoma</z:mpath> &gt; 1 cm: 44%; <z:mpath ids='MPATH_270'>adenoma</z:mpath> of unspecified diameter: 51% </plain></SENT>
<SENT sid="7" pm="."><plain>In a direct comparison with gFOBT of <z:mpath ids='MPATH_270'>adenoma</z:mpath> &gt; 1 cm in diameter, 47% tested positive with the faecal M2-PK test, whereas the gFOBT detected only 27% </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: We recommend faecal M2-PK as a routine test for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening </plain></SENT>
<SENT sid="9" pm="."><plain>Faecal M2-PK closes a gap in clinical practice because it detects <z:mp ids='MP_0001914'>bleeding</z:mp> and non-<z:mp ids='MP_0001914'>bleeding</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:mpath ids='MPATH_270'>adenoma</z:mpath> with high sensitivity and specificity </plain></SENT>
</text></document>